A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)

NCT00072969 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

132

Enrollment

NIH

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Daclizumab

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)